Voyager Therapeutics (VYGR) Competitors $3.28 +0.08 (+2.50%) Closing price 07/3/2025 03:33 PM EasternExtended Trading$3.20 -0.07 (-2.29%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. STOK, SION, IOVA, CDXC, GHRS, EOLS, XNCR, KALV, AUTL, and SANAShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Stoke Therapeutics (STOK), Sionna Therapeutics (SION), Iovance Biotherapeutics (IOVA), ChromaDex (CDXC), GH Research (GHRS), Evolus (EOLS), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Autolus Therapeutics (AUTL), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Its Competitors Stoke Therapeutics Sionna Therapeutics Iovance Biotherapeutics ChromaDex GH Research Evolus Xencor KalVista Pharmaceuticals Autolus Therapeutics Sana Biotechnology Voyager Therapeutics (NASDAQ:VYGR) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Do analysts recommend VYGR or STOK? Voyager Therapeutics presently has a consensus target price of $13.39, suggesting a potential upside of 308.23%. Stoke Therapeutics has a consensus target price of $23.20, suggesting a potential upside of 102.00%. Given Voyager Therapeutics' higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more volatility and risk, VYGR or STOK? Voyager Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Do institutionals and insiders have more ownership in VYGR or STOK? 48.0% of Voyager Therapeutics shares are held by institutional investors. 6.4% of Voyager Therapeutics shares are held by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is VYGR or STOK more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Voyager Therapeutics' net margin of -126.49%. Stoke Therapeutics' return on equity of 19.08% beat Voyager Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-126.49% -27.36% -21.06% Stoke Therapeutics 26.33%19.08%15.72% Does the media refer more to VYGR or STOK? In the previous week, Stoke Therapeutics had 11 more articles in the media than Voyager Therapeutics. MarketBeat recorded 11 mentions for Stoke Therapeutics and 0 mentions for Voyager Therapeutics. Stoke Therapeutics' average media sentiment score of 0.18 beat Voyager Therapeutics' score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Voyager Therapeutics Neutral Stoke Therapeutics Neutral Which has stronger earnings & valuation, VYGR or STOK? Voyager Therapeutics has higher revenue and earnings than Stoke Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$80M2.27-$65M-$1.46-2.25Stoke Therapeutics$36.56M17.15-$88.98M$0.7914.54 SummaryStoke Therapeutics beats Voyager Therapeutics on 12 of the 17 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.08M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-2.2521.5627.4020.24Price / Sales2.27281.35419.60118.25Price / CashN/A41.9536.6357.47Price / Book0.607.518.085.67Net Income-$65M-$55.05M$3.16B$248.47M7 Day Performance10.81%4.71%2.84%3.32%1 Month Performance-1.20%4.89%3.69%5.20%1 Year Performance-57.57%5.82%35.30%21.35% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics3.6763 of 5 stars$3.28+2.5%$13.39+308.2%-57.6%$177.08M$80M-2.25100STOKStoke Therapeutics4.035 of 5 stars$11.59+0.1%$23.20+100.2%-9.4%$632.78M$190.91M14.67100Analyst ForecastSIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$622.15MN/A0.0035Positive NewsInsider TradeIOVAIovance Biotherapeutics4.7136 of 5 stars$1.85-6.6%$12.22+560.7%-76.3%$617.77M$164.07M-1.49500Trending NewsCDXCChromaDex3.2398 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120GHRSGH Research1.9356 of 5 stars$11.68-5.1%$32.00+174.0%+23.7%$607.71MN/A-14.7810EOLSEvolus3.6182 of 5 stars$9.38+1.1%$23.75+153.2%-15.7%$604.82M$266.27M-10.54170XNCRXencor4.026 of 5 stars$8.41-1.5%$28.00+232.9%-54.8%$598.54M$110.49M-2.75280KALVKalVista Pharmaceuticals4.1859 of 5 stars$11.93-1.8%$24.83+108.2%+1.5%$593.16MN/A-3.21100Upcoming EarningsAUTLAutolus Therapeutics2.581 of 5 stars$2.21+7.8%$9.32+321.7%-32.1%$588.17M$9.01M-2.51330Positive NewsSANASana Biotechnology2.629 of 5 stars$2.60-0.4%$10.80+315.4%-38.8%$586.25MN/A-2.95380Analyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies Stoke Therapeutics Alternatives Sionna Therapeutics Alternatives Iovance Biotherapeutics Alternatives ChromaDex Alternatives GH Research Alternatives Evolus Alternatives Xencor Alternatives KalVista Pharmaceuticals Alternatives Autolus Therapeutics Alternatives Sana Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
